AstraZeneca will pay AI drug-discovery company insitro up to $1.5 billion, mostly in milestones, to hunt for new treatment targets for liver disease MASH and cardiomyopathies using machine-learning models trained on human cellular data.
WearOptimo unveiled a new AI-native wearable sensor that reaches just under the skin to capture richer bioimpedance data at the Abu Dhabi Future Health Summit, part of an intensifying race to extract deeper physiological insight from wearable AI.
Google's new Health Guardian AI suite brings passive blood pressure and insulin resistance trend tracking to Fitbit Air, but the most useful features require a $9.99-a-month subscription, raising questions about equitable access to early health warnings.
The FDA's comment window on regulating generative AI medical devices closed October 19, with a proposed two-axis risk framework and physician-style competency testing emerging as the leading ideas for overseeing autonomous clinical AI.
University of Pennsylvania researchers used AI to analyze 150,000 Reddit posts from gray-market users of unapproved weight-loss drug retatrutide, surfacing side-effect patterns that formal surveillance systems don't capture.
ARPA-H's new ADVOCATE program aims to produce an FDA-authorized clinical AI agent within 39 months, a far more compressed timeline than medical AI has typically taken, testing whether agentic AI can meet clinical safety standards that fast.
The FDA's comment period on regulating generative AI medical devices closed October 19, with the American Hospital Association pushing for a risk-based framework as the agency works toward formal 2027 guidance covering AI in mental health and surgery.
Optellum's lung cancer risk AI, the first both FDA-cleared and Medicare-reimbursed tool of its kind, is now integrated into RapidAI's platform, a combination that could meaningfully speed adoption compared to AI tools lacking payer coverage.
FDA-cleared AI tool TumorSight Risk uses a patient's existing breast MRI to predict cancer recurrence risk without added scans, joining a growing wave of cleared cancer-imaging AI tools even as researchers push for outcomes data beyond accuracy.
Oura's new partnership with clinical platform Fullscript puts smart ring health data directly in front of practitioners, a step toward normalizing wearable data in real care decisions.